These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 29641707)
1. New and developing therapies for atopic dermatitis. Hajar T; Gontijo JRV; Hanifin JM An Bras Dermatol; 2018; 93(1):104-107. PubMed ID: 29641707 [TBL] [Abstract][Full Text] [Related]
2. [Current and upcoming treatments of adult atopic dermatitis]. Lacour JP Ann Dermatol Venereol; 2017 Dec; 144 Suppl 5():VS29-VS37. PubMed ID: 29433635 [TBL] [Abstract][Full Text] [Related]
3. New and emerging therapies for paediatric atopic dermatitis. Vakharia PP; Silverberg JI Lancet Child Adolesc Health; 2019 May; 3(5):343-353. PubMed ID: 30904349 [TBL] [Abstract][Full Text] [Related]
4. Itch in Atopic Dermatitis Management. Kamata Y; Tominaga M; Takamori K Curr Probl Dermatol; 2016; 50():86-93. PubMed ID: 27578076 [TBL] [Abstract][Full Text] [Related]
5. Systemic therapy of atopic dermatitis in children. Ricci G; Dondi A; Patrizi A; Masi M Drugs; 2009; 69(3):297-306. PubMed ID: 19275273 [TBL] [Abstract][Full Text] [Related]
6. Health literacy and topical corticosteroid adherence in parents of children with atopic dermatitis in France. Halioua B; Taieb C; Clarke J; Ribeyre C; Merhand S; Demessant-Flavigny AL; Seneschal J J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):e1417-e1419. PubMed ID: 37458523 [No Abstract] [Full Text] [Related]
10. Use of an oral phosphodiesterase-4 inhibitor (apremilast) for the treatment of chronic, severe atopic dermatitis: a case report. Farahnik B; Beroukhim K; Nakamura M; Abrouk M; Zhu TH; Singh R; Lee K; Bhutani T; Koo J; Liao W Dermatol Online J; 2017 May; 23(5):. PubMed ID: 28537861 [TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies for the treatment of atopic dermatitis. Renert-Yuval Y; Guttman-Yassky E Curr Opin Allergy Clin Immunol; 2018 Aug; 18(4):356-364. PubMed ID: 29870461 [TBL] [Abstract][Full Text] [Related]
12. EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers. Bakker DS; Ariens LFM; Giovannone B; Hijnen D; Delemarre EM; Knol E; Nierkens S; de Bruin-Weller MS; Thijs JL; Drylewicz J Allergy; 2020 Dec; 75(12):3287-3289. PubMed ID: 33305359 [No Abstract] [Full Text] [Related]
13. Therapeutic management of atopic dermatitis. Jarrell L Nurse Pract; 2024 Jun; 49(6):39-46. PubMed ID: 38941080 [TBL] [Abstract][Full Text] [Related]
15. Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial. Simpson EL; Parnes JR; She D; Crouch S; Rees W; Mo M; van der Merwe R J Am Acad Dermatol; 2019 Apr; 80(4):1013-1021. PubMed ID: 30550828 [TBL] [Abstract][Full Text] [Related]
16. Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas. Draelos ZD Curr Med Res Opin; 2008 Apr; 24(4):985-94. PubMed ID: 18284804 [TBL] [Abstract][Full Text] [Related]
17. Atopic dermatitis: the new frontier. Harris VR; Cooper AJ Med J Aust; 2017 Oct; 207(8):351-356. PubMed ID: 29020907 [TBL] [Abstract][Full Text] [Related]
18. Dupilumab for off-label treatment of moderate to severe childhood atopic dermatitis. Jorge E; Clark J Cutis; 2018 Sep; 102(3):201-204. PubMed ID: 30372706 [TBL] [Abstract][Full Text] [Related]